300630 Hainan Poly Pharm
- 14.94
- +0.27+1.84%
Hainan Poly Pharm News
Hainan Poly Pharm. Co., Ltd (SZSE:300630) Might Not Be As Mispriced As It Looks After Plunging 28%
The Hainan Poly Pharm. Co., Ltd (SZSE:300630) share price has fared very poorly over the last month, falling by a substantial 28%. Instead of being rewarded, shareholders who have already held thro
Prednisolone Pharmaceuticals (300630.SZ): Voriconazole injection was approved for marketing by the Norwegian Medicines Agency
Puri Pharmaceuticals (300630.SZ) announced that the company recently received a voriconazole injection issued by the Norwegian Medicines Agency...
The annual report letter discloses that Puli Pharmaceuticals (300630.SZ) was ordered by the Hainan Securities Regulatory Bureau to decide on corrective measures
Puli Pharmaceuticals (300630.SZ) issued an announcement. The company recently received Hainan supervision from the China Securities Regulatory Commission...
Is Weakness In Hainan Poly Pharm. Co., Ltd (SZSE:300630) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Hainan Poly Pharm (SZSE:300630) has had a rough three months with its share price down 19%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usu
Prednisolone Pharmaceuticals (300630.SZ): Voriconazole injection was approved for marketing by the Finnish National Drug Administration
Puri Pharmaceuticals (300630.SZ) announced that the company recently received a voriconazole injection issued by the Finnish National Drug Administration...
Hainan Poly Pharm Gets Nod to Market Voriconazole Injection in Sweden
Hainan Poly Pharm (SHE:300630) received marketing authorization from Sweden's Medical Products Agency for its voriconazole injection, according to the company's filing on the Shenzhen Stock Exchange.
Hainan Poly Pharm Gets Nod to Market Skin Infection Drug in Germany
Hainan Poly Pharm (SHE:300630) obtained a marketing authorization from Germany's drug regulator for its daptomycin for injection, the Chinese pharmaceutical company said in its filing on the Shenzhen
Priori Pharmaceuticals (300630.SZ): Daptomycin for injection obtained marketing approval from the German Federal Institute for Drugs and Medical Devices (BfArM)
On April 3, Gelonghui Pharmaceuticals (300630.SZ) announced that the company recently received a marketing license for injectable daptomycin issued by the German Federal Agency for Drugs and Medical Devices (“BfArM”). Daptomycin is a cyclic lipopeptide antibiotic first studied by Lilly (Lilly) and developed by Cubist Pharmaceuticals. On September 12, 2003, the US Food and Drug Administration approved an injectable daptomycin preparation after a rapid trial procedure. The trade name CUBICIN is clinically used to treat complex skin and skin tissue infections and bacteremia caused by Staphylococcus aureus
Puli Pharmaceuticals (300630.SZ) obtains drug GMP compliance inspection notice
Gelonghui announced on April 1, Puli Pharmaceutical (300630.SZ) that the company recently received the “Drug GMP Compliance Inspection Notice” issued by the Hainan Drug Administration. After drug GMP compliance inspection, it complies with the requirements of the “Pharmaceutical Production Quality Management Specification” (2010 edition). The acquisition of the “Pharmaceutical GMP Compliance Inspection Notice” indicates that the company's relevant products and production lines meet GMP requirements, which helps the company to continue to maintain stable product quality and production capacity, meet market demand, and ensure the company's normal production and operation.
Puri Pharmaceuticals (300630.SZ): Phenylephrine hydrochloride injection obtained marketing approval from the US Food and Drug Administration (FDA)
On March 18, Gelonghui Pharmaceuticals (300630.SZ) announced that the company recently received a marketing license for phenylephrine hydrochloride injections issued by the US Food and Drug Administration (“FDA”). Phenylephrine hydrochloride is an alpha adrenergic receptor agonist that interacts with alpha adrenergic receptors on vascular smooth muscle cells to cause cell activation and vasoconstriction. Phenylephrine hydrochloride injections have been used clinically for more than 50 years, and are now widely sold in the United States, Europe, Japan, China and other countries.
Hainan Poly Pharm's (SZSE:300630) Earnings Have Declined Over Three Years, Contributing to Shareholders 53% Loss
Hainan Poly Pharm. Co., Ltd (SZSE:300630) shareholders should be happy to see the share price up 14% in the last month. But that is small recompense for the exasperating returns over three years.
Puli Pharmaceuticals (300630.SZ): Synthetic biology companies currently accumulate varieties such as ecdoine, simeglutide, rhododendine, etc.
Gelonghui March 13 丨 An investor asked Puli Pharmaceuticals (300630.SZ) on the investor interactive platform, “What synthetic biology products does the company have?” The company replied that the varieties currently accumulated by the company in the field of synthetic biology include ecdoine, simeglutide, rhododendine, etc. Other projects under development are also continuing, and the company will continue to accumulate products in the field of synthetic biology in the future. For details, please refer to the relevant information disclosed in the periodic report.
Hainan Poly Pharm's Brivaracetam Injection Gets FDA's Nod to Enter US Market; Shares Up 3%
Hainan Poly Pharm (SHE:300630) obtained approval from the US Food and Drug Administration for the abbreviated new drug application for its brivaracetam injection. The approval allows the Chinese pharm
Prixetam (300630.SZ): Bricetam injection temporarily approved by the US FDA
Puri Pharmaceuticals (300630.SZ) announced that the company recently received the US Food and Drug Administration (hereinafter referred to as...
Hainan Poly Pharm. Co., Ltd (SZSE:300630) Surges 4.9%; Retail Investors Who Own 47% Shares Profited Along With Insiders
Key Insights Hainan Poly Pharm's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 10 investors have a majority
Hainan Poly Pharm's Epilepsy Drug Gets FDA's Greenlight to Enter US Market
Chinese pharmaceutical firm Hainan Poly Pharm (SHE:300630) received approval from the US Food and Drug Administration to market its lacosamide injection in the US. The drug is used to treat partial-on
Puri Pharmaceuticals (300630.SZ): Lacosamide injection obtained marketing approval from the US Food and Drug Administration (FDA)
Gelonghui, Feb. 18: Puli Pharmaceuticals (300630.SZ) announced that the company recently received a marketing license for lacosamide injections issued by the US Food and Drug Administration (“FDA”). Indications are (1) treatment of partial seizure seizures in patients aged 4 years and above; (2) adjuvant treatment of primary generalized tonic-clonic seizures in patients aged 4 and above. Lacosamide is one of a series of functional amino acids and has been shown to have anticonvulsant effects in different preclinical models and clinical studies. In vitro electrophysiological studies have shown that lacosamide selectively increases voltage-gated sodium channel slow loss
Investors Holding Back On Hainan Poly Pharm. Co., Ltd (SZSE:300630)
Hainan Poly Pharm. Co., Ltd's (SZSE:300630) price-to-earnings (or "P/E") ratio of 20.7x might make it look like a buy right now compared to the market in China, where around half of the companies have
Puli Pharmaceuticals (300630.SZ): Currently, two product fields have been established, including cosmetics products and health food products
Gelonghui, January 29丨Puli Pharmaceutical (300630.SZ) said on the investor interactive platform that in 2022, the company established Zhejiang Puli Health Technology Co., Ltd., and simultaneously established the Big Health Research Institute to lay out forward-looking, strategic, and key health fields, target strategic goals for the next 3-5 years, highlight solutions to actual problems in the health industry, and provide products and services to healthy, sub-healthy people or some patients to make them feel healthier and fit, and delay the aging process or prevent diseases before they occur. At present, two product fields have been established, including cosmetics products and health food products, which focus on the company
Minsheng Securities: The policy favors the transfer of overseas drugs to domestic production, optimistic about domestic CDMO leaders
The transfer of drugs produced overseas to domestic production ushered in favorable policies, and China's high-quality production capacity is expected to accelerate its entry into the supply chain of overseas pharmaceutical companies.
Analysis
Price Target
No Data
